Cidara Therapeutics (NASDAQ:CDTX) announced its quarterly earnings data on Thursday. The biotechnology company reported ($0.49) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.60) by $0.11, Fidelity Earnings reports.
Shares of Cidara Therapeutics stock traded down $0.09 during trading on Friday, hitting $4.04. 7,029 shares of the stock traded hands, compared to its average volume of 71,753. The company has a current ratio of 7.11, a quick ratio of 7.11 and a debt-to-equity ratio of 0.12. The firm has a market capitalization of $115.14 million, a PE ratio of -1.27 and a beta of 1.84. Cidara Therapeutics has a 52 week low of $3.36 and a 52 week high of $8.55.
A number of brokerages have issued reports on CDTX. ValuEngine upgraded Cidara Therapeutics from a “sell” rating to a “hold” rating in a research note on Tuesday, July 17th. Cantor Fitzgerald reiterated a “buy” rating and set a $15.00 price target on shares of Cidara Therapeutics in a research note on Wednesday, August 8th. Zacks Investment Research upgraded Cidara Therapeutics from a “hold” rating to a “buy” rating and set a $5.00 price target for the company in a research note on Tuesday, July 24th. Needham & Company LLC set a $14.00 price target on Cidara Therapeutics and gave the stock a “buy” rating in a research note on Thursday, August 9th. Finally, Citigroup began coverage on Cidara Therapeutics in a report on Wednesday, July 25th. They set a “buy” rating and a $8.00 price objective on the stock. Two equities research analysts have rated the stock with a hold rating and five have issued a buy rating to the company’s stock. Cidara Therapeutics presently has a consensus rating of “Buy” and a consensus target price of $11.60.
Cidara Therapeutics, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of anti-infectives for the treatment of diseases. Its lead product candidate is rezafungin acetate, a molecule in the echinocandin class of antifungals for the treatment and prevention of serious invasive fungal infections, including candidemia and invasive candidiasis, fungal infections associated with high mortality rates.
Featured Article: Hedge Funds – How They Work For Investors
Receive News & Ratings for Cidara Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cidara Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.